Clinerion and Semicrol Integrate Patient Network Explorer and Fundanet CTMS to Enable End-to-End Clinical Trial Management
Clinerion and Semicrol announce a collaboration which will integrate the functionality of Clinerion's Patient Network Explorer with Semicrol's Fundanet CTMS. The partnership will integrate patient data throughout the clinical trial process, from planning to reporting of results.
BASEL, SWITZERLAND and SANTANDER, SPAIN, Sept. 10, 2018 /PRNewswire-PRWeb/ -- The technical and commercial collaboration between the two companies will integrate the functionality of Clinerion's Patient Network Explorer with Semicrol's Fundanet Clinical Trials Management System (CTMS), enabling the automated, efficient sharing of patient data from a hospital's electronic health records system to the CTMS running a clinical trial at that hospital.
The collaboration will give clinical trial sponsors and managers unified tools to manage trial data and workflows throughout the clinical trial process, from planning to reporting of results. This will enable a broader approach in clinical trials, drug development support and better outcomes for patients. Patient data privacy is preserved, and patient data remains within the hospital IT infrastructure throughout.
Fundanet CTMS is a world-class clinical trial management system designed to provide quick and easy access to study or subject information utilizing simple and intuitive navigation. Patient Network Explorer aggregates patient insights from anonymized patient records throughout Clinerion's global network of partner hospitals to provide services for clinical trial protocol feasibility, site selection, and patient search and identification, as well as generating real-world data for medical access applications.
"We have seen a significant shift in recent years in the complexity of clinical research recruitment processes and the amount of time needed to identify eligible patients to be successful in the clinical trial enrollment," said Vicente Alciturri, International Director of Semicrol. "In order to meet the changing needs of the research marketplace, we sought out a partner who shared the same core values as us for helping researchers conduct the best possible research and improve operations. We found that partner in Clinerion. The technology flexibility and years of experience makes Clinerion an ideal fit for Fundanet CTMS and an exciting new offering for the clinical research Institutes, CROs and pharma industry as a whole in Spain, Portugal and Latin America. This integrated solution will allow users to reduce redundancy, obtain directly access to high-quality data, and make decisions faster. We look forward to a great partnership."
"Semicrol is one of the innovative market players in the world of software solutions for the clinical research and we are pleased to partner with them in bringing a joint offer to hospitals and trial sites," says Ian Rentsch, CEO of Clinerion. The complementarity of Patient Network Explorer and Fundanet CTMS creates a combined service which offers more than the sum of its parts."
Semicrol and Clinerion will present their collaboration for the first time at the BIOSPAIN Congress at Seville, Spain, on September 25th-27th, 2018.
About Clinerion
Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion's Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion's proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.
Clinerion website: http://www.clinerion.com
Clinerion's Patient Network Explorer: http://www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer
For more information, please contact:
Le Vin Chin
Director, Head of Marketing and Communications
Clinerion Ltd
Margarethenstrasse 47, CH-4053 Basel, Switzerland
Tel.: +41 61 865 60 54
media(at)clinerion(dot)com
About Semicrol SL
Semicrol, the creator of Fundanet CTMS, is a leader in cloud-based software solutions for the clinical research industry and is dedicated to solving problems and providing systems that make the research process more efficient and more profitable throughout the software framework.
Fundanet CTMS is a world-class clinical trial management system designed to provide quick and easy access to study or subject information utilizing simple and intuitive navigation.
Semicrol Headquarter is based in Santander (Spain) and has local offices in Mexico and Bogotá (Colombia) for the LATAM region. Established in 1979, Semicrol comprises around 70 people devoted to consultancy, software development, implanting and maintaining information systems and applications for Hospitals, Research Institutes, Universities, Pharma companies, CROs and medical devices companies.
Semicrol's website: http://www.semicrol.es
Semicrol's Fundanet Suite: http://www.fundanet.es
For more information, please contact:
Vicente Alciturri Fernández
International Director
SEMICROL S.L.
C/ Isabel Torres, 7, 39011 Santander, Cantabria, Spain
Tel.: +34 942 314 224
vicente(dot)alciturri(dot)fernandez(at)semicrol(dot)com
SOURCE Clinerion
Share this article